Introduction
============

In 2012, colorectal cancer (CRC) is the third and second most commonly diagnosed malignancy in males and females, respectively, worldwide, with an estimated 1,360,600 new CRC cases and 693,900 CRC-related mortality occurring annually.[@b1-ott-9-6641] This type of malignancy involves a more frequent sporadic CRC (sCRC) and a less frequent hereditary form. The increasing CRC incidence and mortality rate have been attributed to an increasingly "Westernized lifestyle," including a decreased consumption of dietary fiber, drinking, smoking, overweight, and being physically inactive.[@b2-ott-9-6641] However, the etiology of CRC is very complicated. A number of altered environmental and genetic factors have been considered as risk factors for CRC.[@b3-ott-9-6641],[@b4-ott-9-6641] Recently, a previous study showed that \~35% of CRC patients could be attributed to certain inherited genetic risk factors.[@b5-ott-9-6641] Identification of these important genetic risk factors correlated with CRC may enrich our view of this complex disease.

The *cyclin D1* (*CCND1*) gene located on chromosome 1q31--32. CCND1 is an important protein for the regulation of the G1--S phase transition of cell cycle. Overexpression or disordered regulation of the *CCND1* gene will break the balance of cell cycle and might lead to abnormalities and consequently result in cellular transformation and malignancy. Recent studies showed that *CCND1* was overexpressed in CRC, which was correlated with a poor clinical outcome and some clinicopathological characteristics.[@b6-ott-9-6641],[@b7-ott-9-6641]

The human *CCND1* gene is very polymorphic (<http://www.ncbi.nlm.nih.gov/SNP>). The *CCND1* rs9344, a G to A polymorphism at nucleotide 870 in exon 4, increases the frequency of alternate splicing. Results of prior studies showed that the A allele of *CCND1* rs9344 G\>A resulted in an increasing level of mRNA (transcript-b) encoding CCND1 protein with an altered C-terminal domain.[@b8-ott-9-6641],[@b9-ott-9-6641] Results of some epidemiologic studies demonstrated that *CCND1* rs9344 G\>A polymorphism might confer CRC risk.[@b10-ott-9-6641]--[@b18-ott-9-6641] Several meta-analyses showed that *CCND1* rs9344 G\>A polymorphism might be a risk factor for CRC, especially in the subgroups of sCRC and Caucasians.[@b19-ott-9-6641]--[@b21-ott-9-6641] However, in these studies, as only a few case--control studies performed on the Asian populations, the power of these pooled analyses might be limited. Recently, more epidemiologic studies focusing on the relationship between *CCND1* rs9344 G\>A polymorphism and CRC risk were conducted among Asians. Considering the vital role of *CCND1* rs9344 G\>A polymorphism for CRC risk, an updated meta-analysis was needed to obtain a more precise assessment.

Materials and methods
=====================

Search strategy
---------------

PubMed and EMBASE online databases (updated to February 11, 2016) were searched using the corresponding keywords related to *CCND1* rs9344 G\>A polymorphism and CRC: cyclin D1 or CCND1; and polymorphism, variant, or single-nucleotide polymorphism; colorectal, rectal, or colon; and cancer, carcinoma, tumor, malignancy, or neoplasm. No language restriction was applied. We also searched the bibliography of reviews, meta-analyses, and all eligible articles to retrieve the potential publications.

Inclusion and exclusion criteria
--------------------------------

The included studies were selected according to the major criteria as follows: 1) case--control studies; 2) the association of *CCND1* rs9344 G\>A polymorphism with CRC risk; 3) CRC cases diagnosed by histopathology; and 4) genotype frequencies to determine the pooled odds ratios (ORs) with their 95% confidence intervals (95% CIs). Accordingly, publications with insufficient data, reviews and meta-analyses, and comments were excluded.

Data extraction
---------------

For each included study, two authors (HQ and CC) extracted the data independently as follows: the first author's surname; year of publication; country where the study was carried out; race (included Asians, Caucasians, and Mixed); the type of CRC (included hereditary non-polyposis colorectal cancer \[HNPCC\] and sCRC); the source of controls (included hospital-based study \[HB\], population-based study, and family-based study); genotyping method; sample size (numbers of cases/controls), genotypes; and the Hardy--Weinberg equilibrium (HWE) in the controls. If these two authors could not reach a consensus, the third author (YW) was consulted to resolve the dispute by discussion.

Statistical analysis
--------------------

The distribution of genotypes in controls was calculated for departure from HWE by an online test (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). The crude ORs with their 95% CIs were used to determine the strength of correlation between *CCND1* rs9344 G\>A polymorphism and CRC risk. Heterogeneity assumption was assessed by the chi-square-based *Q*-test and *I*^2^ test. *I*^2^\>50% or *P*\<0.10 indicates statistical heterogeneity among studies,[@b22-ott-9-6641] so the pooled ORs and CIs were measured by the random-effects model (the DerSimoian and Laird method).[@b23-ott-9-6641] Otherwise, the fixed-effects model (the Mantel--Haenszel method) was used.[@b24-ott-9-6641] In order to check the ethnicity and the type of CRC effects, subgroup analyses were performed. Moreover, one-way sensitivity analysis was performed. Publication bias was tested by visual inspection of funnel plots and formally determined by Begg's adjusted rank correlation test and Egger' linear regression test.[@b25-ott-9-6641] All statistical calculations were conducted with STATA version 12.0 (Stata Corporation, College Station, TX, USA). All *P*-values were two-sided, and *P*\<0.05 was defined as statistically significant.

Results
=======

Characteristics
---------------

A total of 198 relevant publications were retrieved. There were several subgroups in certain publications,[@b15-ott-9-6641],[@b16-ott-9-6641],[@b26-ott-9-6641] and we treated them separately. We listed the major screening process in [Figure 1](#f1-ott-9-6641){ref-type="fig"}. Finally, there were 28 eligible studies included in the pooled analysis.[@b12-ott-9-6641]--[@b18-ott-9-6641],[@b26-ott-9-6641]--[@b42-ott-9-6641] There were 9 studies conducted in Asians,[@b12-ott-9-6641],[@b13-ott-9-6641],[@b15-ott-9-6641],[@b18-ott-9-6641],[@b27-ott-9-6641],[@b30-ott-9-6641],[@b33-ott-9-6641],[@b37-ott-9-6641] 16 studies conducted in Caucasians,[@b14-ott-9-6641]--[@b17-ott-9-6641],[@b26-ott-9-6641],[@b28-ott-9-6641],[@b32-ott-9-6641],[@b34-ott-9-6641]--[@b36-ott-9-6641],[@b38-ott-9-6641]--[@b41-ott-9-6641] and 3 studies conducted in mixed populations.[@b29-ott-9-6641],[@b31-ott-9-6641],[@b42-ott-9-6641] Of these articles, 22 investigated sCRC,[@b12-ott-9-6641]--[@b18-ott-9-6641],[@b26-ott-9-6641]--[@b38-ott-9-6641] and 6 investigated HNPCC.[@b16-ott-9-6641],[@b26-ott-9-6641],[@b39-ott-9-6641]--[@b42-ott-9-6641] And the detailed characteristics of the included studies[@b12-ott-9-6641]--[@b18-ott-9-6641],[@b26-ott-9-6641]--[@b42-ott-9-6641] and the distribution of the *CCND1* rs9344 G\>A polymorphism as well as alleles are listed in [Tables 1](#t1-ott-9-6641){ref-type="table"} and [2](#t2-ott-9-6641){ref-type="table"}, respectively.

Quantitative synthesis
----------------------

In total, 28 eligible studies[@b12-ott-9-6641]--[@b18-ott-9-6641],[@b26-ott-9-6641]--[@b42-ott-9-6641] with 5,784 CRC cases and 7,858 controls were included in our meta-analysis. Overall, the *CCND1* rs9344 G\>A polymorphism was associated with the overall CRC risk in four genetic models (A vs G: OR, 1.12; 95% CI: 1.03--1.21, *P*=0.005; AA vs GG: OR, 1.25; 95% CI: 1.06--1.48, *P*=0.008; AA+GA vs GG: OR, 1.18; 95% CI: 1.05--1.33, *P*=0.007; AA vs GA+GG: OR, 1.13; 95% CI: 1.05--1.28, *P*=0.042; [Table 3](#t3-ott-9-6641){ref-type="table"} and [Figure 2](#f2-ott-9-6641){ref-type="fig"}). In a subgroup analysis by CRC type, the *CCND1* rs9344 G\>A polymorphism was associated with an increased risk of sCRC in three genetic models (A vs G: OR, 1.13; 95% CI: 1.04--1.23, *P*=0.004; AA vs GG: OR, 1.28; 95% CI: 1.07--1.54, *P*=0.008; AA+GA vs GG: OR, 1.20; 95% CI: 1.06--1.36, *P*=0.004; [Table 3](#t3-ott-9-6641){ref-type="table"} and [Figure 2](#f2-ott-9-6641){ref-type="fig"}), but not of HNPCC. In a subgroup analysis by ethnicity, an increased CRC risk was found among Caucasians in two genetic models (A vs G: OR, 1.11; 95% CI: 1.00--1.23, *P*=0.049; AA+GA vs GG: OR, 1.16; 95% CI: 1.01--1.33, *P*=0.041; [Table 3](#t3-ott-9-6641){ref-type="table"} and [Figure 3](#f3-ott-9-6641){ref-type="fig"}), and among Asians in one genetic model (A vs G: OR, 1.17; 95% CI: 1.00--1.36, *P*=0.048; [Table 3](#t3-ott-9-6641){ref-type="table"} and [Figure 3](#f3-ott-9-6641){ref-type="fig"}), but not mixed populations.

Tests for publication bias, sensitivity analyses, and heterogeneity
-------------------------------------------------------------------

Begg's funnel plot and Egger' linear regression test were harnessed to examine potential publication bias. As shown in [Figure 4](#f4-ott-9-6641){ref-type="fig"}, no significant publication bias was detected in our study (Begg's test *P*=0.514; Egger's test *P*=0.259).

Influence of an individual study on the pooled ORs and CIs was also determined by omitting it in turn and repeating the meta-analysis.[@b43-ott-9-6641] The results indicated that no individual study significantly altered the pooled ORs and CIs ([Figure 5](#f5-ott-9-6641){ref-type="fig"}).

As shown in [Table 3](#t3-ott-9-6641){ref-type="table"}, there was significant heterogeneity in all genetic models. Because ethnicity, the type of CRC, and source of controls can affect the heterogeneity, subgroup analyses were conducted. Results showed that Asians, Caucasians, population-based study, HB study, and sCRC subgroups may contribute to the major source of heterogeneity.

Discussion
==========

CCND1 may act as an important regulator in the evolution of malignancy by influencing cell proliferation, differentiation, and apoptosis. It has been reported that the G1--S transition of the cell cycle is controlled by sequential activation of cyclin/cyclin-dependent kinase (CDK) complexes.[@b44-ott-9-6641] The CCND1, a vital cell cycle regulatory protein, regulates transition of G1--S phase during cell division. High activity of CCND1 leads to premature cell passage through the G1--S transition, resulting in proliferation of unrepaired DNA damage and genetic errors, thus leading to selective advantage for abnormal cell propagation.[@b45-ott-9-6641] Previous studies indicated that CCND1 was overexpressed in a number of malignancies.[@b6-ott-9-6641],[@b46-ott-9-6641] Owing to these important roles in carcinogenesis, polymorphisms of *CCND1* may be implicated in accelerating the development and/or progression of CRC.

Of late, numerous epidemiologic investigations focused on the relationship of the *CCND1* polymorphism with CRC risk.[@b12-ott-9-6641]--[@b18-ott-9-6641],[@b26-ott-9-6641]--[@b42-ott-9-6641] The most prevalent *CCND1* gene polymer phism, rs9344 G\>A, has been most widely explored. High activity of CCND1 is common in a lot of human tumors.[@b47-ott-9-6641],[@b48-ott-9-6641] Several case--control studies have reported a positive signal of the *CCND1* rs9344 G\>A polymorphism with the risk of CRC;[@b10-ott-9-6641]--[@b16-ott-9-6641] however, others have reported negative signal.[@b17-ott-9-6641],[@b18-ott-9-6641] Because of conflicting results and the insufficient sample size of individual studies, the final decision was far from certain. Because meta-analysis is a powerful way for pooling the results of all included studies with a more power, it can get more robust results than an individual study.[@b49-ott-9-6641] Our findings showed that the presence of the *CCND1* rs9344 A allele, which elevate CCND1 activity,[@b8-ott-9-6641],[@b9-ott-9-6641] might confer the susceptibility to CRC. In addition, subgroup analyses were performed regarding ethnicity and the type of CRC for this polymorphism. *CCND1* rs9344 G\>A polymorphism increased the risk of CRC among Asians, Caucasians, and sCRC. Results of the current meta-analysis indicated the influence of the *CCND1* rs9344 G\>A polymorphism and diversity on the type of CRC. However, our results should be interpreted with very caution. For HNPCC, only six studies with small sample sizes were included in this group, which may restrict the statistical power to obtain a final decision.[@b16-ott-9-6641],[@b26-ott-9-6641],[@b39-ott-9-6641]--[@b42-ott-9-6641] When stratified by ethnicity, the *CCND1* rs9344 G\>A polymorphism was associated with CRC risk in both Asians and Caucasians. Additionally, in other genetic models, a borderline risk of CRC was also observed in these two ethnicities. Results of several previous meta-analyses showed that the *CCND1* rs9344 G\>A polymorphism might be a risk factor for CRC, especially in the subgroups of sCRC and Caucasians.[@b19-ott-9-6641]--[@b21-ott-9-6641] Our results were very analogous to these pooled analyses. In addition, we also found that the *CCND1* rs9344 G\>A polymorphism might be a risk factor for CRC risk in Asians.

The *CCND1* rs9344 G allele may provide an optimal splice donor site and produce a full transcript for CCND1 (transcript a), whereas the *CCND1* rs9344 A allele results in a truncated transcript (transcript b).[@b47-ott-9-6641],[@b50-ott-9-6641],[@b51-ott-9-6641] The well-described transcript (transcript a) interacts with and activates the downstream molecules, such as G1 CDK, CDK4, and CDK6. Then, the CCND1--CDK complex phosphorylates and inhibits the retinoblastoma tumor suppressor, which is necessary for the G1--S transition.[@b52-ott-9-6641] However, a truncated transcript (transcript b) encodes the protein short of the point estimation by sequential testing (PEST) region in the C-terminal domain[@b47-ott-9-6641] and decreases phosphorylation ability of retinoblastoma.[@b53-ott-9-6641] On the other hand, the transcript b has a longer half-life than transcript a, which may result in an overexpression of CCND1. Subsequently, the *CCND1* rs9344 G→A substitution could lead to facilitation of cell proliferation and increase the susceptibility of malignancy.[@b50-ott-9-6641] The findings of our meta-analysis were consistent with the conclusion of previous functional studies mentioned earlier. The epidemiologic investigations provided evidence suggesting that CRC carcinogenesis may be multiple steps that involve both individual's genetic and environmental factors. In the future, larger epidemiologic studies with a well-designed methodology are needed to confirm or refute these associations. Results of our pooled analysis may prompt further clinic investigation of diagnosis and prevention strategies.

There were some merits in this meta-analysis. First, the current meta-analysis was the most extensively study which explored the relationship of the *CCND1* rs9344 G\>A polymorphism with CRC susceptibility. Second, our results first confirmed that the *CCND1* rs9344 G\>A polymorphism was associated with CRC susceptibility among Asians.

Limitations
===========

There were some limitations of our study. First, in some included studies, controls were selected from family member and non-cancer hospital patients, which might result in misclassification bias. Second, large heterogeneity was observed in our meta-analysis, which means our findings should be interpreted with caution. Finally, our findings were based on unadjusted ORs and CIs, while a more precise measurement should be adjusted by multiple risk factors, such as family history, smoking status, drinking, diabetes, body mass index, etc.

Conclusion
==========

In summary, this meta-analysis suggests that the *CCND1* rs9344 G\>A polymorphism is correlated with increased risk of CRC. Moreover, these relationships were different across different cancer types of CRC, suggesting that large sample and well-designed epidemiologic studies are warranted to confirm or refute our findings.
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![Flow diagram of candidate studies selection process.\
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![Meta-analysis with a random--effects model in the different type for the association between *CCND1* rs9344 G\>A polymorphism and CRC risk (A vs G genetic model).\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; CRC, colorectal cancer; HNPCC, hereditary nonpolyposis colorectal cancer; OR, odds ratio; sCRC, sporadic colorectal cancer.](ott-9-6641Fig2){#f2-ott-9-6641}

![Meta-analysis with a random--effects model in different races for the association between the *CCND1* rs9344 G\>A polymorphism and CRC risk (A vs G genetic model).\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; CRC, colorectal cancer; OR, odds ratio.](ott-9-6641Fig3){#f3-ott-9-6641}

![Begg's funnel plot of meta-analysis of the relationship between the *CCND1* rs9344 G\>A polymorphism and CRC risk (AA vs GA+GG genetic model).\
**Abbreviations:** CRC, colorectal cancer; OR, odds ratio; SE, standard error.](ott-9-6641Fig4){#f4-ott-9-6641}

![Sensitivity analysis of the influence of A vs G genetic model in overall CRC meta-analysis (random--effects estimates).\
**Abbreviations:** CI, confidence interval; CRC, colorectal cancer.](ott-9-6641Fig5){#f5-ott-9-6641}

###### 

Characteristics of the candidate studies in the meta-analysis

  Study                                   Year   Country            Ethnicity    Type of CRC   Genotyping method   No of case/control   Source of controls
  --------------------------------------- ------ ------------------ ------------ ------------- ------------------- -------------------- --------------------
  Govatati et al[@b12-ott-9-6641]         2014   India              Asians       sCRC          DNA sequencing      103/107              HB
  Sameer et al[@b27-ott-9-6641]           2013   India              Asians       sCRC          PCR-RFLP            130/160              PB
  Jelonek et al[@b17-ott-9-6641]          2010   Poland             Caucasians   sCRC          PCR-RFLP            50/153               PB
  Yaylim-Eraltan et al[@b28-ott-9-6641]   2010   Turkey             Caucasians   sCRC          PCR-RFLP            57/117               HB
  Kanaan et al[@b29-ott-9-6641]           2010   USA                Mixed        sCRC          PCR-HLC             75/93                HB
  Liu et al[@b30-ott-9-6641]              2010   China              Asians       sCRC          PCR-RFLP            373/838              PB
  Forones et al[@b31-ott-9-6641]          2008   Brazil             Mixed        sCRC          PCR-RFLP            123/120              HB
  Tan et al[@b32-ott-9-6641]              2008   Germany            Caucasians   sCRC          PCR-RFLP            498/600              PB
  Talseth et al[@b39-ott-9-6641]          2008   Australia/Poland   Caucasians   HNPCC         TaqMan              157/153              HB
  Grunhage et al[@b26-ott-9-6641]         2008   Germany            Caucasians   HNPCC         PCR-RFLP            98/218               HB
  Grunhage et al[@b26-ott-9-6641]         2008   Germany            Caucasians   sCRC          PCR-RFLP            96/218               HB
  Jing et al[@b37-ott-9-6641]             2008   China              Asians       sCRC          TaqMan              104/205              HB
  Josifovski et al[@b38-ott-9-6641]       2007   Macedonia          Caucasians   sCRC          PCR-RFLP            331/101              HB
  Kruger et al[@b40-ott-9-6641]           2006   Germany            Caucasians   HNPCC         Multiplex-PCR       315/245              PB
  Probst-Hensch et al[@b33-ott-9-6641]    2006   Singapore          Asians       sCRC          TaqMan              300/1,169            PB
  Schernhammer et al[@b34-ott-9-6641]     2006   USA                Caucasians   sCRC          TaqMan              610/1,237            PB
  Jiang et al[@b13-ott-9-6641]            2006   India              Asians       sCRC          PCR-RFLP            301/291              HB
  Hong et al[@b18-ott-9-6641]             2005   Singapore          Asians       sCRC          PCR-RFLP            254/101              PB
  Grieu et al[@b35-ott-9-6641]            2003   Australia          Caucasians   sCRC          PCR-SSCP            569/327              HB
  Le Marchand et al[@b15-ott-9-6641]      2003   USA                Asians       sCRC          PCR-RFLP            70/83                PB
  Le Marchand et al[@b15-ott-9-6641]      2003   USA                Asians       sCRC          PCR-RFLP            296/380              PB
  Le Marchand et al[@b15-ott-9-6641]      2003   USA                Caucasians   sCRC          PCR-RFLP            138/161              PB
  Porter et al[@b16-ott-9-6641]           2002   UK                 Caucasians   HNPCC         PCR-RFLP            99/171               PB
  Porter et al[@b16-ott-9-6641]           2002   UK                 Caucasians   sCRC          PCR-RFLP            235/171              PB
  Bala and Peltomaki[@b41-ott-9-6641]     2001   Finland            Caucasians   HNPCC         PCR-SSCP            146/186              FB
  Kong et al[@b14-ott-9-6641]             2001   USA                Caucasians   sCRC          PCR-SSCP            156/152              PB
  McKay et al[@b36-ott-9-6641]            2000   UK                 Caucasians   sCRC          PCR-RFLP            100/101              PB
  Kong et al[@b42-ott-9-6641]             2000   USA                Mixed        HNPCC         PCR-SSCP            49/37                FB

**Abbreviations:** FB, family-based study; HB, hospital-based study; HNPCC, hereditary nonpolyposis colorectal cancer; PB, population-based; PCR-HLC, polymerase chain reaction high-performance liquid chromatography; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PCR-SSCP, polymerase chain reaction single-stranded conformation polymorphism; sCRC, sporadic colorectal cancer.

###### 

Distribution of *CCND1* rs9344 G\>A polymorphism genotypes and alleles

  Study                                   Year   Case   Control   Case   Control   HWE                                     
  --------------------------------------- ------ ------ --------- ------ --------- ----- ----- ----- ----- ------- ------- -----
  Govatati et al[@b12-ott-9-6641]         2014   54     39        10     71        33    3     59    147   39      175     Yes
  Sameer et al[@b27-ott-9-6641]           2013   19     70        41     41        76    43    152   108   162     158     Yes
  Jelonek et al[@b17-ott-9-6641]          2010   12     33        5      44        71    38    43    57    147     159     Yes
  Yaylim-Eraltan et al[@b28-ott-9-6641]   2010   9      28        20     29        60    28    68    46    116     118     Yes
  Kanaan et al[@b29-ott-9-6641]           2010   19     39        17     24        48    21    73    77    90      96      Yes
  Liu et al[@b30-ott-9-6641]              2010   66     187       120    160       429   249   427   319   927     749     Yes
  Forones et al[@b31-ott-9-6641]          2008   36     66        21     34        67    19    108   138   105     135     Yes
  Tan et al[@b32-ott-9-6641]              2008   120    263       115    147       310   143   493   503   596     604     Yes
  Talseth et al[@b39-ott-9-6641]          2008   34     78        45     42        80    31    168   146   142     164     Yes
  Grunhage et al[@b26-ott-9-6641]         2008   13     50        35     48        109   61    120   76    231     205     Yes
  Grunhage et al[@b26-ott-9-6641]         2008   24     43        29     48        109   61    101   91    231     205     Yes
  Jing et al[@b37-ott-9-6641]             2008   11     61        32     41        113   51    125   83    215     195     Yes
  Josifovski et al[@b38-ott-9-6641]       2007   77     153       100    25        51    25    353   307   101     101     Yes
  Kruger et al[@b40-ott-9-6641]           2006   110    144       61     73        121   51    266   364   223     267     Yes
  Probst-Hensch et al[@b33-ott-9-6641]    2006   56     132       112    207       548   414   356   244   1,376   962     Yes
  Schernhammer et al[@b34-ott-9-6641]     2006   125    311       174    264       593   380   659   561   1,353   1,121   Yes
  Jiang et al[@b13-ott-9-6641]            2006   46     130       125    56        145   90    380   222   325     257     Yes
  Hong et al[@b18-ott-9-6641]             2005   55     128       71     12        50    39    270   238   128     74      Yes
  Grieu et al[@b35-ott-9-6641]            2003   142    313       114    90        158   79    541   597   316     338     Yes
  Le Marchand et al[@b15-ott-9-6641]      2003   5      35        30     18        35    30    95    45    95      71      Yes
  Le Marchand et al[@b15-ott-9-6641]      2003   75     143       78     96        195   89    299   293   373     387     Yes
  Le Marchand et al[@b15-ott-9-6641]      2003   29     75        34     50        85    26    143   133   137     185     Yes
  Porter et al[@b16-ott-9-6641]           2002   30     47        22     60        81    30    91    107   141     201     Yes
  Porter et al[@b16-ott-9-6641]           2002   55     128       52     60        81    30    232   238   141     201     Yes
  Bala and Peltomaki[@b41-ott-9-6641]     2001   50     70        26     47        97    42    122   170   181     191     Yes
  Kong et al[@b14-ott-9-6641]             2001   36     71        49     45        84    23    169   143   130     174     Yes
  McKay et al[@b36-ott-9-6641]            2000   25     58        17     34        50    17    92    108   84      118     Yes
  Kong et al[@b42-ott-9-6641]             2000   9      36        4      10        21    6     44    54    33      41      Yes

**Abbreviation:** HWE, Hardy--Weinberg equilibrium.

###### 

Meta-analysis of the *CCND1* rs9344 G\>A polymorphism and CRC risk

  Group               No of study   A vs G                  AA vs GG      AA+GA vs GG   AA vs GA+GG                                                                                                                   
  ------------------- ------------- ----------------------- ------------- ------------- ----------------------- ----------- --------- ----------------------- ----------- ------- ----------------------- ----------- -------
  Total               28            **1.12 (1.03--1.21)**   **0.005**     0.001         **1.25 (1.06--1.48)**   **0.008**   \<0.001   **1.18 (1.05--1.33)**   **0.007**   0.013   **1.13 (1.0--1.28)**    **0.042**   0.005
  Ethnicity                                                                                                                                                                                                           
   Asians             9             **1.17 (1.00--1.36)**   **0.048**     0.004         1.38 (0.99--1.94)       0.059       0.002     1.26 (0.96--1.65)       0.092       0.005   1.18 (0.98--1.42)       0.074       0.092
   Caucasians         16            **1.11 (1.00--1.23)**   **0.049**     0.005         1.23 (1.00--1.53)       0.055       0.005     **1.16 (1.01--1.33)**   **0.041**   0.090   1.13 (0.95--1.35)       0.167       0.005
   Mixed              3             1.01 (0.79--1.30)       0.944         1.000         0.99 (0.58--1.71)       0.978       0.925     1.06 (0.71--1.58)       0.767       0.653   0.95 (0.60--1.51)       0.830       0.519
  Type of CRC                                                                                                                                                                                                         
   sCRC               22            **1.13 (1.04--1.23)**   **0.004**     0.002         **1.28 (1.07--1.54)**   **0.008**   0.001     **1.20 (1.06--1.36)**   **0.004**   0.045   1.14 (1.00--1.31)       0.054       0.004
   HNPCC              6             1.06 (0.86--1.32)       0.578         0.035         1.13 (0.73--1.76)       0.581       0.037     1.08 (0.78--1.51)       0.630       0.051   1.10 (0.88--1.37)       0.420       0.177
  Source of control                                                                                                                                                                                                   
   HB                 11            **1.19 (1.08--1.30)**   \<**0.001**   0.161         **1.38 (1.14--1.68)**   **0.001**   0.140     **1.27 (1.08--1.48)**   **0.003**   0.484   **1.25 (1.07--1.45)**   **0.004**   0.134
   PB                 15            1.09 (0.99--1.21)       0.085         0.003         1.21 (0.97--1.51)       0.088       0.001     1.16 (0.99--1.37)       0.065       0.012   1.09 (0.94--1.27)       0.263       0.013
   FB                 2             0.80 (0.61--1.06)       0.120         0.404         0.60 (0.34--1.08)       0.089       0.778     0.77 (0.50--1.18)       0.227       0.106   0.69 (0.42--1.15)       0.157       0.516

**Note:** Statistically significant values are shown in bold.

**Abbreviations:** CRC, colorectal cancer; CI, confidence interval; FB, family-based study; HB, hospital-based study; HNPCC, hereditary nonpolyposis colorectal cancer; HWE, Hardy--Winberg equilibrium; OR, odds ratio; PB, population-based; sCRC, sporadic colorectal cancer.

[^1]: These authors contributed equally to this work
